在STEMI患者中早期启动sacubitril/valsartan改善了心室重塑
Hongyuan Wang1, Yanping Wang1, Xinjun Zhang1
1Department of Cardiology, Jiangshan People's Hospital Quzhou 450001, Zhejiang, China.
American journal of translational research
|July 17, 2025
概括
在ST升高心肌梗塞 (STEMI) 患者的早期sacubitril/valsartan治疗改善了心脏功能并减少了损伤标志物. 这种方法增强了心室重塑和患者预后,没有不良影响.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- ST升高心肌梗塞 (STEMI) 是一种需要及时干预的危急情况.
- 左心室重塑显著影响患者在STEMI后的预后.
研究的目的:
- 调查早期萨库比特里尔/瓦尔萨坦给药对左心室重塑和STEMI患者预后的影响.
- 评估与单独使用瓦尔沙坦相比,萨库比特里尔/瓦尔沙坦在STEMI治疗中的疗效.
主要方法:
- 对150名STEMI患者的回顾性分析.
- 70名接受早期萨库比特里尔/瓦尔萨坦治疗的患者与80名接受瓦尔萨坦治疗的患者进行了比较.
- 对心声学参数和心脏损伤生物标志物的评估.
主要成果:
- 萨库比特里尔/瓦尔沙坦组显示左心室喷射率改善和心室尺寸减少.
- 在sacubitril/valsartan组中,心脏损伤生物标志物 (BNP,Troponin) 和炎症标志物显著减少.
- 早期sacubitril/valsartan观察到增加的中风体积和减少的左心室末缩和末缩体积.
结论:
- 在STEMI患者中早期启动sacubitril/valsartan显著改善了心室重塑.
- 治疗导致心声回声学参数的增强和损伤和炎症生物标志物的减少.
- 没有观察到不良事件的增加或功能受损.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513
Heart Failure V: Medical Management
27
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
27
Acute Coronary Syndrome I: Introduction
80
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
80
Acute Coronary Syndrome IV: Interprofessional Care
32
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32
Aortic Regurgitation III: Medical Management
47
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
47


